Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint | Zendy

Sandrine Lemaire | Zendy; Klaudia Kosowska-Shick | Zendy; Peter C. Appelbaum | Zendy; Y. Glupczynski | Zendy; Françoise Van Bambeke | Zendy; Paul M. Tulkens | Zendy

Open Access

Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint

Author(s) -

Sandrine Lemaire,

Klaudia Kosowska-Shick,

Peter C. Appelbaum,

Y. Glupczynski,

Françoise Van Bambeke,

Paul M. Tulkens

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq478

Subject(s) - moxifloxacin , linezolid , clindamycin , staphylococcus aureus , microbiology and biotechnology , methicillin resistant staphylococcus aureus , antibiotics , antibacterial agent , intracellular , biology , medicine , chemistry , bacteria , vancomycin , biochemistry , genetics

Co-trimoxazole, clindamycin and linezolid are used to treat community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections, but little is known about intracellular activity. Moxifloxacin is active against intracellular methicillin-susceptible S. aureus (MSSA), but CA-MRSA has not been studied.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research